Detalhe da pesquisa
1.
Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer.
N Engl J Med
; 389(22): 2063-2075, 2023 Nov 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-37861218
2.
Incidence, Correlates, and Prognostic Significance of Mixed Response in Advanced Non-small Cell Lung Cancer.
Oncologist
; 29(4): 342-349, 2024 Apr 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38207008
3.
A process to reanalyze clinical DNA sequencing data for biomarker matching in the Lung-MAP Master Protocol.
Oncologist
; 29(6): e843-e847, 2024 Jun 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38597608
4.
Sotorasib for Lung Cancers with KRAS p.G12C Mutation.
N Engl J Med
; 384(25): 2371-2381, 2021 06 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-34096690
5.
Validation of a Molecular Diagnostic Test for Circulating Tumor DNA by Next-Gen Sequencing.
Int J Mol Sci
; 24(21)2023 Oct 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-37958763
6.
Differential prognostic effect of systemic inflammation in patients with non-small cell lung cancer treated with immunotherapy or chemotherapy: A post hoc analysis of the phase 3 OAK trial.
Cancer
; 128(16): 3067-3079, 2022 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35727053
7.
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.
N Engl J Med
; 381(21): 2020-2031, 2019 11 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-31562796
8.
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.
N Engl J Med
; 378(22): 2093-2104, 2018 May 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-29658845
9.
Biomarkers for immune checkpoint inhibition in non-small cell lung cancer (NSCLC).
Cancer
; 126(2): 260-270, 2020 01 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31691957
10.
The BiTE (bispecific T-cell engager) platform: Development and future potential of a targeted immuno-oncology therapy across tumor types.
Cancer
; 126(14): 3192-3201, 2020 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32401342
11.
Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials.
Cancer
; 126(22): 4867-4877, 2020 11 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32914866
12.
First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer.
N Engl J Med
; 376(25): 2415-2426, 2017 06 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-28636851
13.
Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis.
Lancet Oncol
; 20(10): 1395-1408, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31422028
14.
Circulating tumor cell and cell-free RNA capture and expression analysis identify platelet-associated genes in metastatic lung cancer.
BMC Cancer
; 19(1): 603, 2019 Jun 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-31215484
15.
Nivolumab plus ipilimumab in non-small-cell lung cancer.
Future Oncol
; 15(19): 2287-2302, 2019 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-31066582
16.
Musashi-2 (MSI2) supports TGF-ß signaling and inhibits claudins to promote non-small cell lung cancer (NSCLC) metastasis.
Proc Natl Acad Sci U S A
; 113(25): 6955-60, 2016 06 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-27274057
17.
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
N Engl J Med
; 373(17): 1627-39, 2015 Oct 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-26412456
18.
Managing adverse effects of immunotherapy.
Clin Adv Hematol Oncol
; 16(5): 364-374, 2018 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-29851932
19.
Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study.
Lancet Oncol
; 18(1): 31-41, 2017 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27932067
20.
Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody-drug conjugate, in patients with solid tumors.
Cancer
; 123(16): 3080-3087, 2017 Aug 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-28440955